ESMO 2018 | MEK inhibitors for melanoma: new combination approved

Paolo Ascierto

MEK pathway inhibitors have been essential in the treatment of melanoma, and recently a new MEK inhibitor combination was approved by the FDA. Here, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, discusses the three MEK inhibitor combinations currently approved for the treatment of melenoma. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video